The lack of accurate tools for diagnosing the severity of prostate cancer creates opportunities for start-ups with novel approaches. Profiles of 3D Biopsy, Blue Earth Diagnostics, UroSens, and Prostate Management Diagnostics.

Prostate Management Diagnostics Inc. was formed to commercialize research on a series of genetic markers, discovered at The Genome Institute at the Washington University School of Medicine that could help determine whether a prostate cancer is indolent or aggressive in patients newly diagnosed with the disease.

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced December 2014-January 2015.